Stocks · News reference
Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate
Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
The Dividend Divide: Pure Dividend Strategy ETF Meets Tech-Driven Growth ETF
iShares Core High Dividend ETF (HDV) and Fidelity High Dividend ETF (FDVV) offer contrasting approaches to dividend investing. HDV emphasizes defensive sectors like energy and staples with lower volatility and a 0.08% expense ratio, while FDVV incorporates tech exposure with higher growth potential but greater volatility and a 0.15% expense ratio. HDV has delivered 12.8% CAGR since 2021 with a 2.9% yield, while FDVV achieved 13.5% CAGR with a 2.8% yield. The choice depends on whether investors prioritize conservative income or growth-oriented dividend strategies.
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight
Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.